Clinical Trial Update: A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ASP0367 in participants with reduced maximum oxygen uptake due to poor systemic oxygen extraction has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

Drugs mentioned

• ASP0367

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction | Phase 1 | Status: TERMINATED